Kura Oncology 2025 Q3 Earnings Revenue Misses Estimates by 75.72%, Net Loss Widens 36.2%

Kura Oncology (KURA) reported fiscal 2025 Q3 earnings on Nov 5, 2025, with results significantly below expectations. , , . , driven by collaboration revenue from its Kyowa Kirin partnership.

Revenue

, . , though the absence of diversified revenue streams highlights operational challenges.

Earnings/Net Income

, , , , in Q3 2024. , exacerbated by rising R&D and G&A expenses.

Price Action

Following the earnings report, .

Post-Earnings Price Action Review

. , , 2025, . , .

CEO Commentary

CEO Troy Wilson emphasized ziftomenib’s regulatory progress, noting the FDA’s PDUFA date remains on track for November 30, 2025. He highlighted robust clinical and commercial readiness, . , underscoring the company’s heavy investment in late-stage trials.

Guidance

Management reiterated focus on the November 30 PDUFA date and advancing KOMET-017 trials. , with no revenue targets provided.

Additional News

Kura announced a second $30 million milestone payment from Kyowa Kirin for the KOMET-017 trial, . The company plans to host a virtual investor event on December 8 to discuss ASH 2025 data updates. Analysts highlighted the $315 million in pending milestone payments and ziftomenib’s potential as a best-in-class therapy for AML.